Source 1review2026MED
Toolkit/EBV-directed CARs
EBV-directed CARs
Taxonomy: Mechanism Branch / Architecture. Workflows sit above the mechanism and technique branches rather than replacing them.
Summary
High-signal enrichment leads were found primarily in PubMed/PMC and ClinicalTrials sources, with strongest support for EBV gp350/LMP1-directed CARs.
Usefulness & Problems
Why this is useful
This construct class refers to CAR-T designs directed against EBV antigens, with gp350 and LMP1 explicitly named in the supplied evidence.; designing EBV-targeted CAR recognition modules; targeting EBV-associated antigens in CAR-T designs
Source:
This construct class refers to CAR-T designs directed against EBV antigens, with gp350 and LMP1 explicitly named in the supplied evidence.
Source:
designing EBV-targeted CAR recognition modules
Source:
targeting EBV-associated antigens in CAR-T designs
Problem solved
It addresses the need for EBV-specific target recognition in antiviral or EBV-associated disease CAR-T strategies.; provides antigen-targeting strategies for EBV-directed CAR-T engineering
Source:
It addresses the need for EBV-specific target recognition in antiviral or EBV-associated disease CAR-T strategies.
Source:
provides antigen-targeting strategies for EBV-directed CAR-T engineering
Problem links
provides antigen-targeting strategies for EBV-directed CAR-T engineering
LiteratureIt addresses the need for EBV-specific target recognition in antiviral or EBV-associated disease CAR-T strategies.
Source:
It addresses the need for EBV-specific target recognition in antiviral or EBV-associated disease CAR-T strategies.
Taxonomy & Function
Primary hierarchy
Mechanism Branch
Architecture: A reusable architecture pattern for arranging parts into an engineered system.
Mechanisms
antigen-specific target recognitionTarget processes
selectionImplementation Constraints
cofactor dependency: cofactor requirement unknownencoding mode: genetically encodedimplementation constraint: context specific validationimplementation constraint: payload burdenoperating role: regulator
It requires an EBV-targeting recognition domain built into a CAR construct. The payload does not provide further execution details.; requires an EBV-directed recognition module such as one targeting gp350 or LMP1
The supplied evidence does not define which EBV-directed design is best or how they compare across settings.; the supplied payload does not provide detailed construct architecture or comparative efficacy
Validation
Cell-freeBacteriaMammalianMouseHumanTherapeuticIndep. Replication
Supporting Sources
Ranked Claims
The review explicitly names gp350 and LMP1 as EBV CAR target leads, and names BRG01 as a gp350-targeted autologous CAR-T product in clinical development.
The review explicitly names HBsAg-related and PreS1-related HBV CAR strategies, including 4D06 and 4D08 as HBV-directed binder leads.
The review explicitly names VRC01, 3BNC117, and 10-1074 as HIV broadly neutralizing antibody-derived CAR binder leads.
Within the supplied evidence, the strongest explicitly supported antiviral CAR design leads are HIV Env/bNAb-based CARs, HBV HBsAg-directed CARs, and EBV gp350/LMP1-directed CARs.
The review explicitly names CCR5-locus knock-in and C34-CXCR4 as HIV-protective engineering features relevant to antiviral CAR-T design.
Approval Evidence
1 source1 linked approval claimfirst-pass slug ebv-directed-cars
High-signal enrichment leads were found primarily in PubMed/PMC and ClinicalTrials sources, with strongest support for EBV gp350/LMP1-directed CARs.
Source:
design landscape summarysupports
Within the supplied evidence, the strongest explicitly supported antiviral CAR design leads are HIV Env/bNAb-based CARs, HBV HBsAg-directed CARs, and EBV gp350/LMP1-directed CARs.
Source:
Comparisons
Source-stated alternatives
The payload highlights both gp350- and LMP1-directed approaches within the EBV CAR space.
Source:
The payload highlights both gp350- and LMP1-directed approaches within the EBV CAR space.
Source-backed strengths
the supplied evidence explicitly identifies gp350- and LMP1-directed CARs as high-signal EBV leads
Source:
the supplied evidence explicitly identifies gp350- and LMP1-directed CARs as high-signal EBV leads
Compared with gp350-directed CAR recognition strategy
The payload highlights both gp350- and LMP1-directed approaches within the EBV CAR space.
Shared frame: source-stated alternative in extracted literature
Strengths here: the supplied evidence explicitly identifies gp350- and LMP1-directed CARs as high-signal EBV leads.
Relative tradeoffs: the supplied payload does not provide detailed construct architecture or comparative efficacy.
Source:
The payload highlights both gp350- and LMP1-directed approaches within the EBV CAR space.
Compared with LMP1-directed CAR recognition strategy
The payload highlights both gp350- and LMP1-directed approaches within the EBV CAR space.
Shared frame: source-stated alternative in extracted literature
Strengths here: the supplied evidence explicitly identifies gp350- and LMP1-directed CARs as high-signal EBV leads.
Relative tradeoffs: the supplied payload does not provide detailed construct architecture or comparative efficacy.
Source:
The payload highlights both gp350- and LMP1-directed approaches within the EBV CAR space.
Ranked Citations
- 1.